Angelini Pharma Deutschland GmbH · Healthcare · Germany
Medium risk. 4 critical or high findings in SSL/TLS, GDPR outside view and 1 other check.
Angelini Pharma Deutschland GmbH is the German subsidiary of the international pharmaceutical division of the private Italian Angelini Group. Established in Germany since 2020, the company focuses on therapeutic areas including Consumer Health and Brain Health, aiming to alleviate neurological disorders and protect mental health. The website presents a professional and consistent brand image, targeting patients, healthcare professionals, and consumers interested in pharmaceutical products. The company operates internationally with multiple subsidiaries across Europe and the USA, reflecting a medium-sized enterprise with a strong market presence. Technically, the website employs modern JavaScript libraries such as jQuery, Slick Carousel, and Magnific Popup, alongside Piwik PRO for analytics, indicating a mature digital infrastructure. The site is mobile-optimized with good SEO and accessibility basics, though no explicit CMS or hosting provider is identified. Performance is moderate, with asynchronous loading of scripts and preconnect hints enhancing speed. From a security perspective, the site enforces HTTPS and uses analytics with anonymization options, but lacks explicit security headers like Content-Security-Policy or X-Frame-Options. No vulnerabilities or exposed sensitive data were detected in the HTML content. Privacy and cookie policies are present and GDPR compliant, with clear contact information provided. However, no dedicated security policy or incident response contacts were found, and no vulnerability disclosure mechanism is published. Overall, the website is trustworthy, professionally maintained, and compliant with privacy regulations. Strategic improvements include enhancing security headers, publishing a security policy, and establishing a vulnerability disclosure process to strengthen security posture and stakeholder trust.
Scanned
NIS2 Art. 21(2)
This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.
GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.
4 findings rated critical or high. Fix these first.
TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.
Could not establish secure connection to retrieve certificate information
What to do: Check if the server is accessible and SSL/TLS is properly configured
These are the privacy signals visitors and data protection authorities look for under GDPR.
GDPR requires explicit consent for non-essential cookies
What to do: Implement a cookie consent banner that appears on first visit
SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.
SPF helps prevent email spoofing
What to do: Add SPF record: "v=spf1 include:_spf.yourmailprovider.com ~all"
DMARC provides email authentication and reporting
What to do: Add DMARC record: "v=DMARC1; p=none; rua=mailto:dmarc@yourdomain.com"
Need hands-on remediation? Email guard@offseq.com
This scan found 14 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.
€25per month
Email alerts on material changes and an exportable JSON history of every change.
Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.
€39.90one-time
Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.
Each check with its score, findings and the evidence it collected.
The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.
Counted in this score
Not counted
Findings that cap the score at 49
Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.
Partial scans
When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.
Risk levels
Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.
Leaked records that mention angelinipharma.de, from OffSeq Breach.
1 subdomain affected
See the 10 newest leaked credentials
A one-off add-on to this report that lists the most recent identifier and password pairs OffSeq Breach holds for angelinipharma.de.
Select it in the checkout above.
Breach keeps ingesting new leaks, so these numbers can grow between scans.
Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.
Automated reading of the public site. Ratings are indicative.
Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.
Retrieved 2026-10-25
Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.
Reviews of this site
Share your experience with angelinipharma.de. Every review is verified by email and published after moderation.
Community rating
No published reviews yet. Be the first to review angelinipharma.de.